Aims: To evaluate three guidelines for selecting short children for diagnostic workup in a general pediatric clinic. Methods: All patients (n = 131) aged 3.00-9.99 years who were referred for growth failure to a general pediatric clinic were evaluated for their medical history and growth and examined. All of them underwent the same standardized diagnostic workup. Retrospectively, the criteria for the diagnostic workup from three guidelines (proposed in the Netherlands, Finland and the UK) were applied, and their sensitivity was assessed. A Dutch reference sample (n = 958) was used for calculating population specificity. Results: In 23 patients (17.6%), a pathological cause of their growth failure was found. The sensitivity of the original Dutch, Finnish and British guidelines was 73.9, 78.3 and 56.5% and their specificity 98.5, 83.7 and 95.8%, respectively. When adding recent growth deflection to the Dutch guideline, sensitivity increased to 87%, but specificity decreased markedly (to 87%). Conclusion: The proposed cutoff values for height standard deviation score and distance to target height/mid-parental height, as used in the Netherlands and Finland, are effective for population growth monitoring, and superior to the monitoring algorithm in the UK. Growth deflection irrespective of height is an important sign of acquired growth disorders, but its specificity is too low for population screening.

Keywords:
Growth monitoring, Growth disorders, Height standard deviation score, Target height, Height deflection
1.
Scherdel P, Salaün JF, Robberecht-Riquet MN, Reali L, Páll G, Jäger-Roman E, Crespo MP, Moretto M, Seher-Zupančič M, Agustsson S, Chalumeau M: Growth monitoring: a survey of current practices of primary care paediatricians in Europe. PLoS One 2013;8:e70871.
2.
Fayter D, Nixon J, Hartley S, Rithalia A, Butler G, Rudolf M, Glasziou P, Bland M, Stirk L, Westwood M: Effectiveness and cost-effectiveness of height-screening programmes during the primary school years: a systematic review. Arch Dis Child 2008;93:278-284.
3.
Grote FK, Oostdijk W, de Muinck Keizer-Schrama SM, van Dommelen P, van Buuren S, Dekker FW, Ketel AG, Moll HA, Wit JM: The diagnostic work up of growth failure in secondary health care; an evaluation of consensus guidelines. BMC Pediatr 2008;8:21.
4.
Grote FK, van Dommelen P, Oostdijk W, de Muinck Keizer-Schrama SM, Verkerk PH, Wit JM, van Buuren S: Developing evidence-based guidelines for referral for short stature. Arch Dis Child 2008;93:212-217.
5.
Oostdijk W, Grote F, Wit JM, et al: NVK guideline short stature. 2008. http://www.nvk.nl/Portals/0/richtlijnen/kleine%20lengte/kleinelengte.pdf (accessed November 24, 2014).
6.
Saari A, Sankilampi U, Hannila ML, Saha MT, Mäkitie O, Dunkel L: Screening of Turner syndrome with novel auxological criteria facilitates early diagnosis. J Clin Endocrinol Metab 2012;97:E2125-E2132.
7.
Health and Social Care Information Centre: National Child Measurement Programme (NCMP). http://www.hscic.gov.uk/ncmp (accessed April 29, 2015).
8.
Hall DM: Growth monitoring. Arch Dis Child 2000;82:10-15.
9.
Freeman JV, Cole TJ, Chinn S, Jones PRM, White EM, Preece MA: Cross sectional stature and weight reference curves for the UK. Arch Dis Child 1995;73:17-24.
10.
Royal College of Paediatrics and Child Health: UK growth chart girls 2012. http://www.rcpch.ac.uk/system/files/protected/page/NEW%20Girls%202-18yrs(4TH%20JAN%202012).pdf (accessed April 29, 2015).
11.
Royal College of Paediatrics and Child Health: UK growth chart boys 2012. http://www.rcpch.ac.uk/system/files/protected/page/NEW%20Boys%202-18yrs%20(4TH%20JAN%202013).pdf (accessed April 29, 2015).
12.
Fredriks AM, van Buuren S, van Heel WJ, Dijkman-Neerincx RH, Verloove-Vanhorick SP, Wit JM: Nationwide age references for sitting height, leg length, and sitting height/height ratio, and their diagnostic value for disproportionate growth disorders. Arch Dis Child 2005;90:807-812.
13.
Rappold G, Blum WF, Shavrikova EP, Crowe BJ, Roeth R, Quigley CA, Ross JL, Niesler B: Genotypes and phenotypes in children with short stature: clinical indicators of SHOX haploinsufficiency. J Med Genet 2007;44:306-313.
14.
Wit JM, Ranke MB, Kelnar CJH: ESPE Classification of Pediatric Endocrine Diagnoses. Horm Res Paediatr 2007;68:1-119.
15.
Hermanussen M, Cole J: The calculation of target height reconsidered. Horm Res 2003;59:180-183.
16.
van Dommelen P, Schönbeck Y, van Buuren S: A simple calculation of the target height. Arch Dis Child 2012;97:182.
17.
Schönbeck Y, Talma H, van Dommelen P, Bakker B, Buitendijk SE, Hirasing RA, van Buuren S: The world's tallest nation has stopped growing taller: the height of Dutch children from 1955 to 2009. Pediatr Res 2013;73:371-377.
18.
Voss LD, Mulligan J, Betts PR, Wilkin TJ: Poor growth in school entrants as an index of organic disease: the Wessex Growth Study. BMJ 1992;305:1400-1402.
19.
Ahmed ML, Allen AD, Sharma A, Macfarlane JA, Dunger DB: Evaluation of a district growth screening programme: the Oxford Growth Study. Arch Dis Child 1993;69:361-365.
20.
Lindsay R, Feldkamp M, Harris D, Robertson J, Rallison M: Utah Growth Study: growth standards and the prevalence of growth hormone deficiency. J Pediatr 1994;125:29-35.
21.
de Muinck Keizer-Schrama SM: Consensus ‘diagnosis of short stature in children'. National Organization for Quality Assurance in Hospitals (in Dutch). Ned Tijdschr Geneeskd 1998;142:2519-2525.
22.
Sankilampi U, Saari A, Laine T, Miettinen PJ, Dunkel L: Use of electronic health records for automated screening of growth disorders in primary care. JAMA 2013;310:1071-1072.
23.
Sisley S, Trujillo MV, Khoury J, Backeljauw P: Low incidence of pathology detection and high cost of screening in the evaluation of asymptomatic short children. J Pediatr 2013;163:1045-1051.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.